Tarsus Pharmaceuticals Inc. Common Stock (TARS)

FairStock Score: 45/100 — MIXED

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.25, providing financial flexibility
• Altman Z-Score of 7.1 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 128.4% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration

AI Analysis

Tarsus Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $2.6 billion. Revenue stands at $535 million, though the company is currently unprofitable. From a quality standpoint, Tarsus shows Altman Z-Score of 7.1 confirms fortress-level solvency and negative ROE indicating losses. On valuation, the stock is 0.5% FCF yield. Growth dynamics show revenue growing at 128.4% and profit growth of 63.8%. Our composite FairStock Score of 45/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Tarsus's 128% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer